These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 18600596

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK.
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [Abstract] [Full Text] [Related]

  • 6. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR.
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [Abstract] [Full Text] [Related]

  • 7. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 8. Incretin-based therapies: mimetics versus protease inhibitors.
    Brubaker PL.
    Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
    [Abstract] [Full Text] [Related]

  • 9. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ, Vilsbøll T, Deacon CF.
    Mol Cell Endocrinol; 2009 Jan 15; 297(1-2):127-36. PubMed ID: 18786605
    [Abstract] [Full Text] [Related]

  • 10. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT.
    J Am Osteopath Assoc; 2010 Mar 15; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ, McGill MA.
    Clin Drug Investig; 2012 Jan 01; 32(1):1-14. PubMed ID: 21958333
    [Abstract] [Full Text] [Related]

  • 14. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J.
    Regul Pept; 2005 Jun 15; 128(2):149-57. PubMed ID: 15780434
    [Abstract] [Full Text] [Related]

  • 15. Extrapancreatic effects of GIP and GLP-1.
    Vella A, Rizza RA.
    Horm Metab Res; 2004 Jun 15; 36(11-12):830-6. PubMed ID: 15655715
    [Abstract] [Full Text] [Related]

  • 16. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK, Vilsbøll T, Holst JJ.
    Curr Protein Pept Sci; 2009 Feb 15; 10(1):46-55. PubMed ID: 19275672
    [Abstract] [Full Text] [Related]

  • 17. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug 15; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.